ESMO 2022: Highlights on ADT duration with post-operative radiotherapy in prostate cancer: RADICALS-HD
Share.
About Author
ONA Editor
The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.
Related Posts
-
Randomised trial finds drug therapy reduces hot flashes during prostate cancer treatment
-
Niraparib and abiraterone acetate dual action tablet receives CHMP positive opinion for BRCA 1/2-mutated metastatic hormone-sensitive prostate cancer
-
Study suggests many men may not need long-term hormone therapy for prostate cancer